Drugs / grapiprant
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03658772 | Sep 2018 → Mar 2023 | colorectal cancer | Arrys Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00392080 | Nov 2006 → Feb 2008 | osteoarthritis | Pfizer | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05041101 | Dec 2021 → Sep 2024 | inflammatory breast carcinoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT03696212 | Jan 2019 → Feb 2021 | lung adenocarcinoma | Arrys Therapeutics | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02538432 | Jun 2017 → Dec 2019 | breast cancer, non-small cell lung carcinoma, prostate cancer | University of Maryland, Baltimore | Withdrawn | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | grapiprant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03658772 ↗ |
| Known as | AAT-007 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3039498 ↗ |
| Known as | CJ-023 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3039498 ↗ |
| Known as | CJ-023,423 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00392080 ↗ |
| Known as | Galliprant | ChEMBL registry synonym — accepted as the source's own label CHEMBL3039498 ↗ |
| Known as | MR-10A7 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3039498 ↗ |
| Known as | RQ-00000007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02538432 ↗ |
| Action | Inhibit | “Prostanoid EP4 receptor antagonist” CHEMBL3039498 ↗1“EP4 Receptor Antagonist” NCT02538432 ↗ |
| Modality | Small molecule | — CHEMBL3039498 ↗ |
| Route | Oral | “taken orally” NCT02538432 ↗ |
| Target | PTGER4 | “Prostanoid EP4 receptor antagonist” CHEMBL3039498 ↗ |